Vindesine

Profil Farmakokinetik

Waktu Paruh (Half-Life) 24 hours.

Volume Distribusi -

Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Hepatic

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

2 Data

1. Exercise caution with grapefruit products. Vindesine is metabolized by CYP3A4, and grapefruit inhibits CYP3A4 metabolism, which may increase vindesine serum levels.
2. Exercise caution with St. John's Wort. Vindesine is metabolized by CYP3A4 and this herb induces CYP3A4 metabolism, which may reduce vindesine serum levels.

Interaksi Obat

917 Data

Denosumab	The risk or severity of adverse effects can be increased when Denosumab is combined with Vindesine.
Peginterferon alfa-2a	The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Vindesine.
Interferon alfa-n1	The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Vindesine.
Interferon alfa-n3	The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Vindesine.
Peginterferon alfa-2b	The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Vindesine.
Interferon gamma-1b	The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Vindesine.
Interferon alfa-2a	The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Vindesine.
Gemtuzumab ozogamicin	The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Vindesine.
Pegaspargase	The risk or severity of adverse effects can be increased when Pegaspargase is combined with Vindesine.
Interferon beta-1b	The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Vindesine.
Interferon alfacon-1	The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Vindesine.
Rituximab	The risk or severity of adverse effects can be increased when Rituximab is combined with Vindesine.
Basiliximab	The risk or severity of adverse effects can be increased when Basiliximab is combined with Vindesine.
Muromonab	The risk or severity of adverse effects can be increased when Muromonab is combined with Vindesine.
Ibritumomab tiuxetan	The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Vindesine.
Tositumomab	The risk or severity of adverse effects can be increased when Tositumomab is combined with Vindesine.
Alemtuzumab	The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Vindesine.
Alefacept	The risk or severity of adverse effects can be increased when Alefacept is combined with Vindesine.
Efalizumab	The risk or severity of adverse effects can be increased when Efalizumab is combined with Vindesine.
Antithymocyte immunoglobulin (rabbit)	The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Vindesine.
Interferon alfa-2b	The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Vindesine.
Daclizumab	The risk or severity of adverse effects can be increased when Daclizumab is combined with Vindesine.
Phenylalanine	The risk or severity of adverse effects can be increased when Phenylalanine is combined with Vindesine.
Bortezomib	The risk or severity of adverse effects can be increased when Bortezomib is combined with Vindesine.
Cladribine	Vindesine may increase the immunosuppressive activities of Cladribine.
Carmustine	The risk or severity of adverse effects can be increased when Carmustine is combined with Vindesine.
Amsacrine	The risk or severity of adverse effects can be increased when Amsacrine is combined with Vindesine.
Bleomycin	The risk or severity of adverse effects can be increased when Bleomycin is combined with Vindesine.
Chlorambucil	The risk or severity of adverse effects can be increased when Chlorambucil is combined with Vindesine.
Raltitrexed	The risk or severity of adverse effects can be increased when Raltitrexed is combined with Vindesine.
Floxuridine	The risk or severity of adverse effects can be increased when Vindesine is combined with Floxuridine.
Indomethacin	The risk or severity of adverse effects can be increased when Vindesine is combined with Indomethacin.
Tioguanine	The risk or severity of adverse effects can be increased when Vindesine is combined with Tioguanine.
Vinorelbine	The risk or severity of adverse effects can be increased when Vindesine is combined with Vinorelbine.
Dexrazoxane	The risk or severity of adverse effects can be increased when Vindesine is combined with Dexrazoxane.
Streptozocin	The risk or severity of adverse effects can be increased when Vindesine is combined with Streptozocin.
Trifluridine	The risk or severity of adverse effects can be increased when Vindesine is combined with Trifluridine.
Gemcitabine	The risk or severity of adverse effects can be increased when Vindesine is combined with Gemcitabine.
Epirubicin	The risk or severity of adverse effects can be increased when Vindesine is combined with Epirubicin.
Lenalidomide	The risk or severity of adverse effects can be increased when Vindesine is combined with Lenalidomide.
Altretamine	The risk or severity of adverse effects can be increased when Vindesine is combined with Altretamine.
Zidovudine	The risk or severity of adverse effects can be increased when Vindesine is combined with Zidovudine.
Cisplatin	The risk or severity of adverse effects can be increased when Vindesine is combined with Cisplatin.
Oxaliplatin	The risk or severity of adverse effects can be increased when Vindesine is combined with Oxaliplatin.
Vincristine	The risk or severity of adverse effects can be increased when Vindesine is combined with Vincristine.
Fluorouracil	The risk or severity of adverse effects can be increased when Vindesine is combined with Fluorouracil.
Propylthiouracil	The risk or severity of adverse effects can be increased when Vindesine is combined with Propylthiouracil.
Pentostatin	The risk or severity of adverse effects can be increased when Vindesine is combined with Pentostatin.
Methotrexate	The risk or severity of adverse effects can be increased when Vindesine is combined with Methotrexate.
Linezolid	The risk or severity of adverse effects can be increased when Vindesine is combined with Linezolid.
Clofarabine	The risk or severity of adverse effects can be increased when Vindesine is combined with Clofarabine.
Prednisone	The risk or severity of adverse effects can be increased when Vindesine is combined with Prednisone.
Pemetrexed	The risk or severity of adverse effects can be increased when Vindesine is combined with Pemetrexed.
Fludrocortisone	The risk or severity of adverse effects can be increased when Vindesine is combined with Fludrocortisone.
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Vindesine is combined with Mycophenolate mofetil.
Tretinoin	The risk or severity of cardiotoxicity can be increased when Vindesine is combined with Tretinoin.
Irinotecan	The risk or severity of adverse effects can be increased when Vindesine is combined with Irinotecan.
Sulfasalazine	The risk or severity of adverse effects can be increased when Vindesine is combined with Sulfasalazine.
Dacarbazine	The risk or severity of adverse effects can be increased when Vindesine is combined with Dacarbazine.
Temozolomide	The risk or severity of adverse effects can be increased when Vindesine is combined with Temozolomide.
Penicillamine	The risk or severity of adverse effects can be increased when Vindesine is combined with Penicillamine.
Mechlorethamine	The risk or severity of adverse effects can be increased when Vindesine is combined with Mechlorethamine.
Azacitidine	The risk or severity of adverse effects can be increased when Vindesine is combined with Azacitidine.
Carboplatin	The risk or severity of adverse effects can be increased when Vindesine is combined with Carboplatin.
Dactinomycin	The risk or severity of adverse effects can be increased when Vindesine is combined with Dactinomycin.
Cytarabine	The risk or severity of adverse effects can be increased when Vindesine is combined with Cytarabine.
Azathioprine	The risk or severity of adverse effects can be increased when Vindesine is combined with Azathioprine.
Hydroxyurea	The risk or severity of adverse effects can be increased when Vindesine is combined with Hydroxyurea.
Mycophenolic acid	The risk or severity of adverse effects can be increased when Vindesine is combined with Mycophenolic acid.
Mercaptopurine	The risk or severity of adverse effects can be increased when Vindesine is combined with Mercaptopurine.
Thalidomide	The metabolism of Vindesine can be increased when combined with Thalidomide.
Melphalan	The risk or severity of adverse effects can be increased when Vindesine is combined with Melphalan.
Fludarabine	The risk or severity of adverse effects can be increased when Vindesine is combined with Fludarabine.
Flucytosine	The risk or severity of adverse effects can be increased when Vindesine is combined with Flucytosine.
Capecitabine	The risk or severity of adverse effects can be increased when Vindesine is combined with Capecitabine.
Trilostane	The risk or severity of adverse effects can be increased when Vindesine is combined with Trilostane.
Procarbazine	The risk or severity of adverse effects can be increased when Vindesine is combined with Procarbazine.
Arsenic trioxide	The risk or severity of adverse effects can be increased when Vindesine is combined with Arsenic trioxide.
Idarubicin	The risk or severity of adverse effects can be increased when Vindesine is combined with Idarubicin.
Estramustine	The risk or severity of adverse effects can be increased when Vindesine is combined with Estramustine.
Lomustine	The risk or severity of adverse effects can be increased when Vindesine is combined with Lomustine.
Eculizumab	The risk or severity of adverse effects can be increased when Vindesine is combined with Eculizumab.
Decitabine	The risk or severity of adverse effects can be increased when Vindesine is combined with Decitabine.
Nelarabine	The risk or severity of adverse effects can be increased when Vindesine is combined with Nelarabine.
Ciclesonide	The risk or severity of adverse effects can be increased when Vindesine is combined with Ciclesonide.
Stepronin	The risk or severity of adverse effects can be increased when Vindesine is combined with Stepronin.
Hydroxychloroquine	The risk or severity of adverse effects can be increased when Vindesine is combined with Hydroxychloroquine.
Castanospermine	The risk or severity of adverse effects can be increased when Vindesine is combined with Castanospermine.
Vorinostat	The risk or severity of adverse effects can be increased when Vindesine is combined with Vorinostat.
2-Methoxyethanol	The risk or severity of adverse effects can be increased when Vindesine is combined with 2-Methoxyethanol.
Brequinar	The risk or severity of adverse effects can be increased when Vindesine is combined with Brequinar.
Thiotepa	The risk or severity of adverse effects can be increased when Vindesine is combined with Thiotepa.
Aldosterone	The risk or severity of adverse effects can be increased when Vindesine is combined with Aldosterone.
Ixabepilone	The risk or severity of adverse effects can be increased when Vindesine is combined with Ixabepilone.
Pirfenidone	The risk or severity of adverse effects can be increased when Vindesine is combined with Pirfenidone.
Belinostat	The risk or severity of adverse effects can be increased when Vindesine is combined with Belinostat.
Trabectedin	The risk or severity of adverse effects can be increased when Vindesine is combined with Trabectedin.
Interferon alfa	The risk or severity of adverse effects can be increased when Vindesine is combined with Interferon alfa.
Glatiramer	The risk or severity of adverse effects can be increased when Vindesine is combined with Glatiramer.
Briakinumab	The risk or severity of adverse effects can be increased when Vindesine is combined with Briakinumab.

Target Protein

Tubulin beta-1 chain TUBB1

Referensi & Sumber

Synthesis reference: Stanislaw Rolski, "Method of preparing vindesine sulfate." U.S. Patent US4259242, issued September, 1965.

Contoh Produk & Brand

Produk: 1 • International brands: 2

Produk

Eldisine Inj 5mg/2ml

Powder, for solution • 5 mg / vial • Intravenous • Canada • Approved

International Brands

Eldesine
Eldisine

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.

Deskripsi

Struktur Molekul 2D

Deskripsi metode visualisasi

1. Pendahuluan & Konsep

2. Sumber Data (Validasi)

3. Algoritma Visualisasi

4. Legenda Visual